To address the needs of emphysema patients who may not be candidates for Zephyr Endobronchial Valves, Pulmonx is introducing therapeutic options such as the AeriSeal System.
The AeriSeal treatment uses a polymeric foam to block diseased regions in the lung to achieve volume reduction and improve breathing function. The treatment is designed for patients with emphysema and is independent of collateral ventilation. AeriSeal received CE mark approval at the end of 2015.
AeriSeal is available in a limited release in selected treatment centers in Europe.